About
Boundless Bio, Inc. Common Stock (NASDAQ:BOLD) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 17 2026
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Mar 17 2026
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
Mar 9 2026
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Mar 4 2026
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Feb 5 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Financials
Revenue
$0
Market Cap
$26.44 M
EPS
-2.60
Translate